Literature DB >> 17497491

Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics.

Jonas Wallvik1, Anders Själander, Lars Johansson, Orjan Bjuhr, Jan-Håkan Jansson.   

Abstract

OBJECTIVES: To examine determinants of bleeding complications during warfarin treatment in an unselected patient population and evaluate possible differences in safety between specialized anticoagulation clinics and primary healthcare centres.
DESIGN: Prospective cohort study. Data were collected with an admission form and medical records were scrutinized in order to pursue all adverse events. Differences between groups were estimated with a t-test and chi-squared test, and univariate and multivariate Cox regression analysis.
SETTING: All patients treated and monitored with oral anticoagulation in primary healthcare centres and specialized anticoagulation clinics in the Sundsvall and Skellefteå region (northern Sweden) during a five-year period.
SUBJECTS: A total of 2731 patients corresponding to 5044 treatment years. MAIN OUTCOME MEASURES: Bleedings were classified as fatal or major. Major bleedings were defined as an event causing admission, prolonged in-hospital care or death.
RESULTS: In total 195 major bleedings occurred corresponding to 3.9% per treatment year, including 34 fatal events (0.67% per treatment year). Patients monitored at the two specialized anticoagulation clinics combined had a major bleeding frequency of 4.1% as compared with 3.9% at primary healthcare units. The frequency of fatal haemorrhage was 0.57% and 0.76%, respectively. The rate of major and fatal bleeding was age related with an increase of 4% and 5%, respectively, per year.
CONCLUSIONS: There was no difference in bleeding complications between patients monitored at primary healthcare centres and specialized anticoagulation clinics. Age was continuously and independently associated with bleeding risk. These study data indicate the need to exercise caution in treatment of the elderly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17497491      PMCID: PMC3379747          DOI: 10.1080/02813430601183108

Source DB:  PubMed          Journal:  Scand J Prim Health Care        ISSN: 0281-3432            Impact factor:   2.581


  21 in total

1.  Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study.

Authors:  Margaret C Fang; Alan S Go; Elaine M Hylek; Yuchiao Chang; Lori E Henault; Nancy G Jensvold; Daniel E Singer
Journal:  J Am Geriatr Soc       Date:  2006-08       Impact factor: 5.562

2.  Anticoagulant treatment of patients in Swedish primary health care. Safety aspects.

Authors:  P E Wändell
Journal:  Eur J Clin Pharmacol       Date:  2001-04       Impact factor: 2.953

3.  Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness.

Authors:  L Kalra; G Yu; I Perez; A Lakhani; N Donaldson
Journal:  BMJ       Date:  2000-05-06

4.  International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle.

Authors:  Nils Kucher; Shannon Connolly; Joshua A Beckman; Lay Har Cheng; Kanella V Tsilimingras; John Fanikos; Samuel Z Goldhaber
Journal:  Arch Intern Med       Date:  2004-10-25

5.  Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

Authors:  P Petersen; G Boysen; J Godtfredsen; E D Andersen; B Andersen
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

Review 6.  Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions.

Authors:  C A Bond; Cynthia L Raehl
Journal:  Pharmacotherapy       Date:  2004-08       Impact factor: 4.705

Review 7.  Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.

Authors:  C S Landefeld; R J Beyth
Journal:  Am J Med       Date:  1993-09       Impact factor: 4.965

Review 8.  Warfarin therapy in older adults: managing treatment in the primary care setting.

Authors:  Pam Perrin Perrero; Deborah F Willoughby; Julie A Eggert; Sandra Harley Counts
Journal:  J Gerontol Nurs       Date:  2004-07       Impact factor: 1.254

9.  Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group.

Authors: 
Journal:  Lancet       Date:  1994-02-26       Impact factor: 79.321

10.  Anticoagulant treatment in primary health care in Sweden - prevalence, incidence and treatment diagnosis: a retrospective study on electronic patient records in a registered population.

Authors:  Gunnar H Nilsson; Ingela Björholt; Hans Johnsson
Journal:  BMC Fam Pract       Date:  2003-04-01       Impact factor: 2.497

View more
  15 in total

1.  Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers.

Authors:  Liat Mlynarsky; Idit Bejarano-Achache; Mordechai Muszkat; Yoseph Caraco
Journal:  Eur J Clin Pharmacol       Date:  2011-11-10       Impact factor: 2.953

Review 2.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Outcomes of warfarin therapy managed by pharmacists via hospital anticoagulation clinic versus online anticoagulation clinic.

Authors:  Hua Cao; Jianmei Wu; Jinhua Zhang
Journal:  Int J Clin Pharm       Date:  2018-06-28

4.  Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics.

Authors:  Charles E Leonard; Colleen M Brensinger; Warren B Bilker; Stephen E Kimmel; Xu Han; Young Hee Nam; Joshua J Gagne; Margaret J Mangaali; Sean Hennessy
Journal:  Int J Cardiol       Date:  2016-11-12       Impact factor: 4.164

Review 5.  Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review.

Authors:  Wendy T Chen; C Michael White; Olivia J Phung; Jeffrey Kluger; Ajibade O Ashaye; Diana M Sobieraj; Sagar Makanji; Vanita Tongbram; William L Baker; Craig I Coleman
Journal:  Mayo Clin Proc       Date:  2011-06       Impact factor: 7.616

6.  Who receives anticoagulant treatment with warfarin and why? A population-based study in Finland.

Authors:  Irma Virjo; Kari Mäkelä; Juhani Aho; Pentti Kalliola; Harri Kurunmäki; Leena Uusitalo; Markku Valli; Suvi Ylinen
Journal:  Scand J Prim Health Care       Date:  2010-09-07       Impact factor: 2.581

7.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

Authors:  Daniel M Witt; Robby Nieuwlaat; Nathan P Clark; Jack Ansell; Anne Holbrook; Jane Skov; Nadine Shehab; Juliet Mock; Tarra Myers; Francesco Dentali; Mark A Crowther; Arnav Agarwal; Meha Bhatt; Rasha Khatib; John J Riva; Yuan Zhang; Gordon Guyatt
Journal:  Blood Adv       Date:  2018-11-27

Review 8.  Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.

Authors:  Thomas P Moyer; Dennis J O'Kane; Linnea M Baudhuin; Carmen L Wiley; Alexandre Fortini; Pamela K Fisher; Denise M Dupras; Rajeev Chaudhry; Prabin Thapa; Alan R Zinsmeister; John A Heit
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

9.  Ten-year experience with acenocoumarol treatment in an ambulatory cohort of Spanish patients.

Authors:  Joan-Carles Trullas-Vila; Josep Bisbe-Company; Adriana Freitas-Ramírez; Silvia Soler-Simon; Vicenta Bisbe-Company; Josep-Maria Roncero-Vidal; Rosa Gispert-Magarolas
Journal:  J Thromb Thrombolysis       Date:  2009-02-19       Impact factor: 2.300

10.  Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical heart valves: a tertiary hospital-based study in Botswana.

Authors:  Elizabeth Botsile; Julius Chacha Mwita
Journal:  Cardiovasc J Afr       Date:  2020-03-16       Impact factor: 1.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.